Kiora Pharmaceuticals, Inc.
KPRX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.35 | 0.02 | -0.01 | -0.02 |
| FCF Yield | -33.39% | -21.30% | -22.29% | 5.96% |
| EV / EBITDA | -4.88 | -4.42 | -2.47 | -3.66 |
| Quality | ||||
| ROIC | -7.84% | -7.61% | -16.45% | -10.29% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -47.49 | 1.77 | 1.23 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | 2,519,742.10% |
| Free Cash Flow Growth | -41.84% | -22.51% | -339.91% | 124.31% |
| Safety | ||||
| Net Debt / EBITDA | 0.27 | 1.76 | 1.49 | 2.06 |
| Interest Coverage | 0.00 | 0.00 | -119.59 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -807.35 | -4,326.00 | -1,097.22 | -4,176.61 |